
Vaxcyte (PCVX) Stock Forecast & Price Target
Vaxcyte (PCVX) Analyst Ratings
Bulls say
Vaxcyte Inc. is positioned favorably due to its promising product pipeline, including the VAX-31 vaccine, which is anticipated to launch in 2028 and is expected to significantly boost revenues, with peak revenue estimates now raised to $6.8 billion. The company’s strong Ph1/2 results and potential regulatory support from the ACIP could lead to a broader adoption of its vaccines, particularly among adults over 50, thereby expanding the addressable market substantially. With ongoing positive clinical data and anticipated upcoming readouts, Vaxcyte is likely to sustain investor interest, reinforcing a positive outlook for its stock in the near term.
Bears say
Vaxcyte Inc. faces significant downside risks related to potential delays in research and development, regulatory hurdles, and disappointing clinical results, which could hinder the commercial feasibility of its vaccine candidates. The underwhelming readout from the VAX-24 Phase 2 trial has contributed to investor disappointment, highlighting heightened expectations in a competitive market, along with the broader impact of stricter governmental stances on vaccine approvals. Furthermore, even in the event of successful clinical outcomes, the potential restriction of Vaxcyte vaccines in national vaccine guidelines could severely limit their commercial prospects, adding to the uncertainty surrounding the company's future performance.
This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.
Vaxcyte (PCVX) Analyst Forecast & Price Prediction
Start investing in Vaxcyte (PCVX)
Order type
Buy in
Order amount
Est. shares
0 shares